We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
+$59.5M
Cap. Flow %
4.02%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.47%
2 Technology 8.46%
3 Industrials 4.82%
4 Financials 2.07%
5 Consumer Discretionary 1.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBTG icon
126
American Express Global Business Travel
GBTG
$4.93B
$714K 0.05%
73,055
-76,945
-51% -$758K
TWNI.U
127
DELISTED
Tailwind International Acquisition Corp. Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant
TWNI.U
$483K 0.03%
48,342
-101,658
-68% -$1.01M
ELEV
128
DELISTED
Elevation Oncology
ELEV
$407K 0.03%
+30,000
New +$371K
IMTXW
129
DELISTED
Immatics N.V. Warrants
IMTXW
$344K 0.02%
100,000
– –
MGIC
130
DELISTED
Magic Software Enterprises
MGIC
$259K 0.02%
+15,976
New +$256K
SRSA
131
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$237K 0.02%
23,900
– –
CERE
132
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$236K 0.02%
9,212
-903,028
-99% -$12.9M
OTLKW
133
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$49K ﹤0.01%
129,500
– –
ATXS
134
DELISTED
Astria Therapeutics
ATXS
– –
-215,667
Closed -$3.74M
BBIO icon
135
BridgeBio Pharma
BBIO
$15.7B
– –
-23,890
Closed -$1.47M
BIDU icon
136
Baidu
BIDU
$37.7B
– –
-25,000
Closed -$5.44M
BMY icon
137
Bristol-Myers Squibb
BMY
$133B
– –
-200,000
Closed -$12.6M
BOLT icon
138
Bolt Biotherapeutics
BOLT
$7.67M
– –
-12,050
Closed -$7.93M
CAMT icon
139
Camtek
CAMT
$6.18B
– –
-79,746
Closed -$2.38M
CLDX icon
140
Celldex Therapeutics
CLDX
$2.99B
– –
-220,320
Closed -$4.54M
CLOU icon
141
PUT
Global X Cloud Computing ETF
CLOU
$240M
– –
-170,600
Closed -$4.39M
CNTB
142
Connect Biopharma Holdings
CNTB
$127M
– –
-50,000
Closed -$925K
COGT icon
143
Cogent Biosciences
COGT
$6.65B
– –
-762,569
Closed -$6.7M
CYBR
144
DELISTED
CyberArk
CYBR
– –
-55,000
Closed -$7.11M
EQ icon
145
Equillium
EQ
$139M
– –
-254,184
Closed -$1.82M
EWTX icon
146
Edgewise Therapeutics
EWTX
$4.13B
– –
-100,000
Closed -$3.25M
DMRA
147
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.78B
– –
-17,921
Closed -$2.72M
HIPO icon
148
Hippo Holdings
HIPO
$830M
– –
-18,720
Closed -$4.68M
ICLN icon
149
PUT
iShares Global Clean Energy ETF
ICLN
$2.31B
– –
-420,000
Closed -$10.2M
IFRX icon
150
InflaRx
IFRX
$250M
– –
-1,000,000
Closed -$3.9M
4 5
6
7 8

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $59.5M of net new capital in Q2 2021, opening 41 new positions and adding to 36 existing holdings. Its largest new stake was Iovance Biotherapeutics: 378,642 shares worth $9.85M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $49.7M trimmed.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.